Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Two tales of Annexin A2 knock-down: One of compensatory effects by antisense RNA and another of a highly active hairpin ribozyme.

Aareskjold E, Grindheim AK, Hollås H, Goris M, Lillehaug JR, Vedeler A.

Biochem Pharmacol. 2019 Aug;166:253-263. doi: 10.1016/j.bcp.2019.05.028. Epub 2019 May 31.

2.

CorA is a copper repressible surface-associated copper(I)-binding protein produced in Methylomicrobium album BG8.

Johnson KA, Ve T, Larsen O, Pedersen RB, Lillehaug JR, Jensen HB, Helland R, Karlsen OA.

PLoS One. 2014 Feb 3;9(2):e87750. doi: 10.1371/journal.pone.0087750. eCollection 2014.

3.

CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia.

Astori A, Fredly H, Aloysius TA, Bullinger L, Mansat-De Mas V, de la Grange P, Delhommeau F, Hagen KM, Récher C, Dusanter-Fourt I, Knappskog S, Lillehaug JR, Pendino F, Bruserud Ø.

Oncotarget. 2013 Sep;4(9):1438-48.

4.

Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma.

Birkeland E, Busch C, Berge EO, Geisler J, Jönsson G, Lillehaug JR, Knappskog S, Lønning PE.

Clin Exp Metastasis. 2013 Oct;30(7):867-76. doi: 10.1007/s10585-013-9587-4. Epub 2013 May 15.

5.

Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.

Berge EO, Huun J, Lillehaug JR, Lønning PE, Knappskog S.

Biochim Biophys Acta. 2013 Mar;1830(3):2790-7.

PMID:
23246812
6.

The Methylococcus capsulatus (Bath) secreted protein, MopE*, binds both reduced and oxidized copper.

Ve T, Mathisen K, Helland R, Karlsen OA, Fjellbirkeland A, Røhr ÅK, Andersson KK, Pedersen RB, Lillehaug JR, Jensen HB.

PLoS One. 2012;7(8):e43146. doi: 10.1371/journal.pone.0043146. Epub 2012 Aug 20.

7.

Human protein N-terminal acetyltransferase hNaa50p (hNAT5/hSAN) follows ordered sequential catalytic mechanism: combined kinetic and NMR study.

Evjenth RH, Brenner AK, Thompson PR, Arnesen T, Frøystein NÅ, Lillehaug JR.

J Biol Chem. 2012 Mar 23;287(13):10081-8. doi: 10.1074/jbc.M111.326587. Epub 2012 Feb 6.

8.

Receptor for activated protein C kinase 1 (RACK1) is overexpressed in papillary thyroid carcinoma.

Myklebust LM, Akslen LA, Varhaug JE, Lillehaug JR.

Thyroid. 2011 Nov;21(11):1217-25. doi: 10.1089/thy.2010.0186. Epub 2011 Oct 18.

PMID:
22007921
9.

The human N-alpha-acetyltransferase 40 (hNaa40p/hNatD) is conserved from yeast and N-terminally acetylates histones H2A and H4.

Hole K, Van Damme P, Dalva M, Aksnes H, Glomnes N, Varhaug JE, Lillehaug JR, Gevaert K, Arnesen T.

PLoS One. 2011;6(9):e24713. doi: 10.1371/journal.pone.0024713. Epub 2011 Sep 15.

10.

Using VAAST to identify an X-linked disorder resulting in lethality in male infants due to N-terminal acetyltransferase deficiency.

Rope AF, Wang K, Evjenth R, Xing J, Johnston JJ, Swensen JJ, Johnson WE, Moore B, Huff CD, Bird LM, Carey JC, Opitz JM, Stevens CA, Jiang T, Schank C, Fain HD, Robison R, Dalley B, Chin S, South ST, Pysher TJ, Jorde LB, Hakonarson H, Lillehaug JR, Biesecker LG, Yandell M, Arnesen T, Lyon GJ.

Am J Hum Genet. 2011 Jul 15;89(1):28-43. doi: 10.1016/j.ajhg.2011.05.017. Epub 2011 Jun 23. Erratum in: Am J Hum Genet. 2011 Aug 12;89(2):345.

11.

Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.

Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Skjønsberg G, Aas T, Schlichting E, Fjösne HE, Nysted A, Lillehaug JR, Lønning PE.

PLoS One. 2011 Apr 27;6(4):e19249. doi: 10.1371/journal.pone.0019249.

12.

Proteome-derived peptide libraries allow detailed analysis of the substrate specificities of N(alpha)-acetyltransferases and point to hNaa10p as the post-translational actin N(alpha)-acetyltransferase.

Van Damme P, Evjenth R, Foyn H, Demeyer K, De Bock PJ, Lillehaug JR, Vandekerckhove J, Arnesen T, Gevaert K.

Mol Cell Proteomics. 2011 May;10(5):M110.004580. doi: 10.1074/mcp.M110.004580. Epub 2011 Mar 7.

13.

Depletion of the human Nα-terminal acetyltransferase A induces p53-dependent apoptosis and p53-independent growth inhibition.

Gromyko D, Arnesen T, Ryningen A, Varhaug JE, Lillehaug JR.

Int J Cancer. 2010 Dec 15;127(12):2777-89. doi: 10.1002/ijc.25275.

14.

RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer.

Knappskog S, Myklebust LM, Busch C, Aloysius T, Varhaug JE, Lønning PE, Lillehaug JR, Pendino F.

Ann Oncol. 2011 Oct;22(10):2208-15. doi: 10.1093/annonc/mdq737. Epub 2011 Feb 16.

PMID:
21325450
15.

The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.

Knappskog S, Bjørnslett M, Myklebust LM, Huijts PE, Vreeswijk MP, Edvardsen H, Guo Y, Zhang X, Yang M, Ylisaukko-Oja SK, Alhopuro P, Arola J, Tollenaar RA, van Asperen CJ, Seynaeve C, Staalesen V, Chrisanthar R, Løkkevik E, Salvesen HB, Evans DG, Newman WG, Lin D, Aaltonen LA, Børresen-Dale AL, Tell GS, Stoltenberg C, Romundstad P, Hveem K, Lillehaug JR, Vatten L, Devilee P, Dørum A, Lønning PE.

Cancer Cell. 2011 Feb 15;19(2):273-82. doi: 10.1016/j.ccr.2010.12.019.

16.

Alterations of the retinoblastoma gene in metastatic breast cancer.

Berge EO, Knappskog S, Lillehaug JR, Lønning PE.

Clin Exp Metastasis. 2011 Mar;28(3):319-26. doi: 10.1007/s10585-011-9375-y. Epub 2011 Jan 21.

17.

Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers.

Berge EO, Knappskog S, Geisler S, Staalesen V, Pacal M, Børresen-Dale AL, Puntervoll P, Lillehaug JR, Lønning PE.

Mol Cancer. 2010 Jul 1;9:173. doi: 10.1186/1476-4598-9-173.

18.

MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC.

Busch C, Geisler J, Lillehaug JR, Lønning PE.

Eur J Cancer. 2010 Jul;46(11):2127-33. doi: 10.1016/j.ejca.2010.04.023. Epub 2010 Jun 10.

PMID:
20541396
19.

Alterations in the p53 pathway and p16INK4a expression predict overall survival in metastatic melanoma patients treated with dacarbazine.

Busch C, Geisler J, Knappskog S, Lillehaug JR, Lønning PE.

J Invest Dermatol. 2010 Oct;130(10):2514-6. doi: 10.1038/jid.2010.138. Epub 2010 May 27. No abstract available.

20.

Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.

Jönsson G, Busch C, Knappskog S, Geisler J, Miletic H, Ringnér M, Lillehaug JR, Borg A, Lønning PE.

Clin Cancer Res. 2010 Jul 1;16(13):3356-67. doi: 10.1158/1078-0432.CCR-09-2509. Epub 2010 May 11.

21.

Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity.

Berge EO, Staalesen V, Straume AH, Lillehaug JR, Lønning PE.

Biochim Biophys Acta. 2010 Mar;1803(3):386-95. doi: 10.1016/j.bbamcr.2010.01.005. Epub 2010 Jan 15.

22.

Inverse correlation between PDGFC expression and lymphocyte infiltration in human papillary thyroid carcinomas.

Bruland O, Fluge Ø, Akslen LA, Eiken HG, Lillehaug JR, Varhaug JE, Knappskog PM.

BMC Cancer. 2009 Dec 8;9:425. doi: 10.1186/1471-2407-9-425.

23.

Human Naa50p (Nat5/San) displays both protein N alpha- and N epsilon-acetyltransferase activity.

Evjenth R, Hole K, Karlsen OA, Ziegler M, Arnesen T, Lillehaug JR.

J Biol Chem. 2009 Nov 6;284(45):31122-9. doi: 10.1074/jbc.M109.001347. Epub 2009 Sep 10.

24.

Application of reverse-phase HPLC to quantify oligopeptide acetylation eliminates interference from unspecific acetyl CoA hydrolysis.

Evjenth R, Hole K, Ziegler M, Lillehaug JR.

BMC Proc. 2009 Aug 4;3 Suppl 6:S5. doi: 10.1186/1753-6561-3-S6-S5.

25.

A novel human NatA Nalpha-terminal acetyltransferase complex: hNaa16p-hNaa10p (hNat2-hArd1).

Arnesen T, Gromyko D, Kagabo D, Betts MJ, Starheim KK, Varhaug JE, Anderson D, Lillehaug JR.

BMC Biochem. 2009 May 29;10:15. doi: 10.1186/1471-2091-10-15.

26.

Proteomics analyses reveal the evolutionary conservation and divergence of N-terminal acetyltransferases from yeast and humans.

Arnesen T, Van Damme P, Polevoda B, Helsens K, Evjenth R, Colaert N, Varhaug JE, Vandekerckhove J, Lillehaug JR, Sherman F, Gevaert K.

Proc Natl Acad Sci U S A. 2009 May 19;106(20):8157-62. doi: 10.1073/pnas.0901931106. Epub 2009 May 6.

27.

Knockdown of human N alpha-terminal acetyltransferase complex C leads to p53-dependent apoptosis and aberrant human Arl8b localization.

Starheim KK, Gromyko D, Evjenth R, Ryningen A, Varhaug JE, Lillehaug JR, Arnesen T.

Mol Cell Biol. 2009 Jul;29(13):3569-81. doi: 10.1128/MCB.01909-08. Epub 2009 Apr 27.

28.

The protein Nalpha-terminal acetyltransferase hNaa10p (hArd1) is phosphorylated in HEK293 cells.

Målen H, Lillehaug JR, Arnesen T.

BMC Res Notes. 2009 Mar 2;2:32. doi: 10.1186/1756-0500-2-32.

29.

Functional involvement of RINF, retinoid-inducible nuclear factor (CXXC5), in normal and tumoral human myelopoiesis.

Pendino F, Nguyen E, Jonassen I, Dysvik B, Azouz A, Lanotte M, Ségal-Bendirdjian E, Lillehaug JR.

Blood. 2009 Apr 2;113(14):3172-81. doi: 10.1182/blood-2008-07-170035. Epub 2009 Jan 30.

PMID:
19182210
30.

The protein acetyltransferase ARD1: a novel cancer drug target?

Arnesen T, Thompson PR, Varhaug JE, Lillehaug JR.

Curr Cancer Drug Targets. 2008 Nov;8(7):545-53. Review.

PMID:
18991565
31.

CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.

Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Østenstad B, Lundgren S, Berge EO, Risberg T, Mjaaland I, Maehle L, Engebretsen LF, Lillehaug JR, Lønning PE.

PLoS One. 2008 Aug 26;3(8):e3062. doi: 10.1371/journal.pone.0003062.

32.

The presence of multiple c-type cytochromes at the surface of the methanotrophic bacterium Methylococcus capsulatus (Bath) is regulated by copper.

Karlsen OA, Lillehaug JR, Jensen HB.

Mol Microbiol. 2008 Oct;70(1):15-26. doi: 10.1111/j.1365-2958.2008.06380.x. Epub 2008 Aug 4.

33.

Identification of the human N(alpha)-acetyltransferase complex B (hNatB): a complex important for cell-cycle progression.

Starheim KK, Arnesen T, Gromyko D, Ryningen A, Varhaug JE, Lillehaug JR.

Biochem J. 2008 Oct 15;415(2):325-31. doi: 10.1042/BJ20080658.

PMID:
18570629
34.

An oxidized tryptophan facilitates copper binding in Methylococcus capsulatus-secreted protein MopE.

Helland R, Fjellbirkeland A, Karlsen OA, Ve T, Lillehaug JR, Jensen HB.

J Biol Chem. 2008 May 16;283(20):13897-904. doi: 10.1074/jbc.M800340200. Epub 2008 Mar 18.

35.

LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro.

Huang TS, Myklebust LM, Kjarland E, Gjertsen BT, Pendino F, Bruserud Ø, Døskeland SO, Lillehaug JR.

Mol Cancer. 2007 Apr 23;6:31.

36.

Mutations and polymorphisms of the p21B transcript in breast cancer.

Knappskog S, Chrisanthar R, Staalesen V, Børresen-Dale AL, Gram IT, Lillehaug JR, Lønning PE.

Int J Cancer. 2007 Aug 15;121(4):908-10.

37.

Breast cancer prognostication and prediction in the postgenomic era.

Lønning PE, Knappskog S, Staalesen V, Chrisanthar R, Lillehaug JR.

Ann Oncol. 2007 Aug;18(8):1293-306. Epub 2007 Feb 21. Review.

PMID:
17317675
38.

P21/WAF1 mutation and drug resistance to paclitaxel in locally advanced breast cancer.

Chrisanthar R, Knappskog S, Staalesen V, Lillehaug JR, Lønning PE.

Int J Cancer. 2007 Jun 15;120(12):2749. No abstract available.

39.

RACK1 regulates Ki-Ras-mediated signaling and morphological transformation of NIH 3T3 cells.

Bjørndal B, Myklebust LM, Rosendal KR, Myromslien FD, Lorens JB, Nolan G, Bruland O, Lillehaug JR.

Int J Cancer. 2007 Mar 1;120(5):961-9.

40.

The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer.

Staalesen V, Knappskog S, Chrisanthar R, Nordgard SH, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Gram IT, Kristensen VN, Børresen-Dale AL, Lillehaug JR, Lønning PE.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6000-4.

41.

A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family.

Knappskog S, Geisler J, Arnesen T, Lillehaug JR, Lønning PE.

Genes Chromosomes Cancer. 2006 Dec;45(12):1155-63. Erratum in: Genes Chromosomes Cancer. 2007 Jul;46(7):716.

PMID:
17001621
42.

Gene expression in poorly differentiated papillary thyroid carcinomas.

Fluge Ø, Bruland O, Akslen LA, Lillehaug JR, Varhaug JE.

Thyroid. 2006 Feb;16(2):161-75.

PMID:
16676402
43.

Characterization of hARD2, a processed hARD1 gene duplicate, encoding a human protein N-alpha-acetyltransferase.

Arnesen T, Betts MJ, Pendino F, Liberles DA, Anderson D, Caro J, Kong X, Varhaug JE, Lillehaug JR.

BMC Biochem. 2006 Apr 25;7:13.

44.

Induction of apoptosis in human cells by RNAi-mediated knockdown of hARD1 and NATH, components of the protein N-alpha-acetyltransferase complex.

Arnesen T, Gromyko D, Pendino F, Ryningen A, Varhaug JE, Lillehaug JR.

Oncogene. 2006 Jul 20;25(31):4350-60. Epub 2006 Mar 6.

PMID:
16518407
45.

Cloning and characterization of hNAT5/hSAN: an evolutionarily conserved component of the NatA protein N-alpha-acetyltransferase complex.

Arnesen T, Anderson D, Torsvik J, Halseth HB, Varhaug JE, Lillehaug JR.

Gene. 2006 Apr 26;371(2):291-5. Epub 2006 Feb 28.

PMID:
16507339
46.

Nuclear localisation of endogenous SUMO-1-modified PDGF-C in human thyroid tissue and cell lines.

Reigstad LJ, Martinez A, Varhaug JE, Lillehaug JR.

Exp Cell Res. 2006 Apr 1;312(6):782-95. Epub 2006 Jan 26.

PMID:
16443219
47.

Identification of a copper-repressible C-type heme protein of Methylococcus capsulatus (Bath). A member of a novel group of the bacterial di-heme cytochrome c peroxidase family of proteins.

Karlsen OA, Kindingstad L, Angelskår SM, Bruseth LJ, Straume D, Puntervoll P, Fjellbirkeland A, Lillehaug JR, Jensen HB.

FEBS J. 2005 Dec;272(24):6324-35.

48.

Analysing the outer membrane subproteome of Methylococcus capsulatus (Bath) using proteomics and novel biocomputing tools.

Berven FS, Karlsen OA, Straume AH, Flikka K, Murrell JC, Fjellbirkeland A, Lillehaug JR, Eidhammer I, Jensen HB.

Arch Microbiol. 2006 Feb;184(6):362-77. Epub 2005 Nov 26.

PMID:
16311759
49.

Interaction between HIF-1 alpha (ODD) and hARD1 does not induce acetylation and destabilization of HIF-1 alpha.

Arnesen T, Kong X, Evjenth R, Gromyko D, Varhaug JE, Lin Z, Sang N, Caro J, Lillehaug JR.

FEBS Lett. 2005 Nov 21;579(28):6428-32. Epub 2005 Nov 2.

50.

Supplemental Content

Loading ...
Support Center